

Resource Summary Report

Generated by [kravitz2](#) on Aug 21, 2026

Fluidigm: CyTOF Helios Mass Cytometer

RRID:SCR_019916

Type: Tool

Proper Citation

Fluidigm: CyTOF Helios Mass Cytometer (RRID:SCR_019916)

Resource Information

URL:

<https://fluidigm.my.salesforce.com/sfc/p/#700000009DAw/a/4u0000019fxF/vgeiyRxF5ALVMw6cEJM>

Proper Citation: Fluidigm: CyTOF Helios Mass Cytometer (RRID:SCR_019916)

Description: Mass cytometer that enables deep profiling of translational and clinical research samples across range of cell surface and intracellular markers. Helios represents newer, more advanced iteration with improvements in throughput, detection range, and software capabilities.

Synonyms: CyTOF Helios, CyTOF Helios Mass Cytometer

Resource Type: instrument resource

Keywords: Fluidigm, Mass Cytometer, Instrument Equipment, Cytometry by Time-of-Flight, Helios

Availability: Commercially available

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_019916.pdf

Resource Name: Fluidigm: CyTOF Helios Mass Cytometer

Resource ID: SCR_019916

Alternate IDs: Model_Number_CyTOF_Helios, SCR_019917

Old URLs: <https://www.fluidigm.com/products/helios>

Record Creation Time: 20220129T080347+0000

Record Last Update: 20260815T182628+0000

Ratings and Alerts

No rating or validation information has been found for Fluidigm: CyTOF Helios Mass Cytometer.

No alerts have been found for Fluidigm: CyTOF Helios Mass Cytometer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Sirc N, et al. (2026) Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models. Cancer research communications, 6(2), 402.

Li Z, et al. (2026) Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(14), 2911.

Alsina M, et al. (2026) Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Cancer immunology research, 14(4), 528.

Maerz MD, et al. (2026) BCG vaccination induces antibacterial effector functions among V α 1/3 T cells that are associated with protection against tuberculosis. Cell reports. Medicine, 102536.

Kogai H, et al. (2025) Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody-Drug Conjugate with BET Protein Degradar in Colorectal, Lung, and Breast Cancer Mouse Models. Molecular cancer therapeutics, 24(3), 392.

Eguchi S, et al. (2025) CXCL10-induced chemotaxis of ex vivo-expanded natural killer cells combined with NKTR-255 enhances anti-tumor efficacy in osteosarcoma. Molecular therapy. Oncology, 33(4), 201051.

Nakazawa M, et al. (2025) Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines. Cancer immunology research, 13(6), 836.

Goggin KE, et al. (2025) Differential Effects of High-Fiber and Low-Fiber Diets on Antitumor Immunity and Colon Tumor Progression in a Murine Model. Cancer prevention research (Philadelphia, Pa.), 18(4), 223.

Tasis A, et al. (2024) Single-Cell Analysis of Bone Marrow CD8⁺ T Cells in Myeloid Neoplasms Reveals Pathways Associated with Disease Progression and Response to

Treatment with Azacitidine. *Cancer research communications*, 4(12), 3067.

Gonzalez-Kozlova E, et al. (2024) Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma. *Cancer research communications*, 4(7), 1726.

Rovira-Clavé X, et al. (2022) Spatial epitope barcoding reveals clonal tumor patch behaviors. *Cancer cell*, 40(11), 1423.

Souza-Moreira L, et al. (2022) Poly(I:C) enhances mesenchymal stem cell control of myeloid cells from COVID-19 patients. *iScience*, 25(5), 104188.

Harpaz N, et al. (2022) Single-cell epigenetic analysis reveals principles of chromatin states in H3.3-K27M gliomas. *Molecular cell*, 82(14), 2696.

Karabacak NM, et al. (2022) Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition. *Cancer research*, 82(6), 1084.

Eiva MA, et al. (2022) Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs. *European journal of immunology*, 52(1), 96.

Penttilä PA, et al. (2021) High dimensional profiling identifies specific immune types along the recovery trajectories of critically ill COVID19 patients. *Cellular and molecular life sciences : CMLS*, 78(8), 3987.

Duraiswamy J, et al. (2021) Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. *Cancer cell*, 39(12), 1623.

Wogslund CE, et al. (2021) High-dimensional immunotyping of tumors grown in obese and non-obese mice. *Disease models & mechanisms*, 14(4).

Anandan S, et al. (2021) Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. *Cancers*, 13(4).

Ausar SF, et al. (2020) Genetically detoxified pertussis toxin displays near identical structure to its wild-type and exhibits robust immunogenicity. *Communications biology*, 3(1), 427.